JP2005508966A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005508966A5 JP2005508966A5 JP2003536220A JP2003536220A JP2005508966A5 JP 2005508966 A5 JP2005508966 A5 JP 2005508966A5 JP 2003536220 A JP2003536220 A JP 2003536220A JP 2003536220 A JP2003536220 A JP 2003536220A JP 2005508966 A5 JP2005508966 A5 JP 2005508966A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound
- group
- preparing
- membered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 41
- 238000004519 manufacturing process Methods 0.000 claims 14
- 238000000034 method Methods 0.000 claims 13
- 125000000623 heterocyclic group Chemical group 0.000 claims 9
- 125000000217 alkyl group Chemical group 0.000 claims 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 6
- 125000002619 bicyclic group Chemical group 0.000 claims 5
- 229910052760 oxygen Inorganic materials 0.000 claims 5
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 4
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 4
- -1 methoxymethoxy Chemical group 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- VTGOHKSTWXHQJK-UHFFFAOYSA-N pyrimidin-2-ol Chemical group OC1=NC=CC=N1 VTGOHKSTWXHQJK-UHFFFAOYSA-N 0.000 claims 4
- 239000012453 solvate Substances 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 239000002253 acid Substances 0.000 claims 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 125000005843 halogen group Chemical group 0.000 claims 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 3
- QMNWYGTWTXOQTP-UHFFFAOYSA-N 1h-triazin-6-one Chemical compound O=C1C=CN=NN1 QMNWYGTWTXOQTP-UHFFFAOYSA-N 0.000 claims 2
- YCIPQJTZJGUXND-UHFFFAOYSA-N Aglaia odorata Alkaloid Natural products C1=CC(OC)=CC=C1C1(C(C=2C(=O)N3CCCC3=NC=22)C=3C=CC=CC=3)C2(O)C2=C(OC)C=C(OC)C=C2O1 YCIPQJTZJGUXND-UHFFFAOYSA-N 0.000 claims 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- KYNSBQPICQTCGU-UHFFFAOYSA-N Benzopyrane Chemical compound C1=CC=C2C=CCOC2=C1 KYNSBQPICQTCGU-UHFFFAOYSA-N 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 150000001350 alkyl halides Chemical class 0.000 claims 2
- 125000004414 alkyl thio group Chemical group 0.000 claims 2
- 230000036506 anxiety Effects 0.000 claims 2
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 208000024714 major depressive disease Diseases 0.000 claims 2
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 208000019116 sleep disease Diseases 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 claims 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- 125000006705 (C5-C7) cycloalkyl group Chemical group 0.000 claims 1
- KEIFWROAQVVDBN-UHFFFAOYSA-N 1,2-dihydronaphthalene Chemical compound C1=CC=C2C=CCCC2=C1 KEIFWROAQVVDBN-UHFFFAOYSA-N 0.000 claims 1
- SDQJTWBNWQABLE-UHFFFAOYSA-N 1h-quinazoline-2,4-dione Chemical compound C1=CC=C2C(=O)NC(=O)NC2=C1 SDQJTWBNWQABLE-UHFFFAOYSA-N 0.000 claims 1
- PZMKGWRBZNOIPQ-UHFFFAOYSA-N 1h-thieno[3,2-d]pyrimidin-4-one Chemical compound OC1=NC=NC2=C1SC=C2 PZMKGWRBZNOIPQ-UHFFFAOYSA-N 0.000 claims 1
- OSEVYTJMMHAQGG-UHFFFAOYSA-N 2-methylsulfanyl-1h-thieno[3,2-d]pyrimidin-4-one Chemical compound N1C(SC)=NC(=O)C2=C1C=CS2 OSEVYTJMMHAQGG-UHFFFAOYSA-N 0.000 claims 1
- SZDUJHZOLZGLMV-UHFFFAOYSA-N 2-sulfanylidene-1h-thieno[3,2-d]pyrimidin-4-one Chemical compound O=C1NC(=S)NC2=C1SC=C2 SZDUJHZOLZGLMV-UHFFFAOYSA-N 0.000 claims 1
- IVRCHBYBKXRNIC-UHFFFAOYSA-N 3-[3-methoxy-4-(2-pyrrolidin-1-ylethoxy)phenyl]-6-phenylthieno[3,2-d]pyrimidin-4-one Chemical compound COC1=CC(N2C(C=3SC(=CC=3N=C2)C=2C=CC=CC=2)=O)=CC=C1OCCN1CCCC1 IVRCHBYBKXRNIC-UHFFFAOYSA-N 0.000 claims 1
- QJDUIALZROAHNX-UHFFFAOYSA-N 3-[3-methoxy-4-(2-pyrrolidin-1-ylethyl)phenyl]-7-phenyl-1,2,3-benzotriazin-4-one Chemical compound COC1=CC(N2C(C3=CC=C(C=C3N=N2)C=2C=CC=CC=2)=O)=CC=C1CCN1CCCC1 QJDUIALZROAHNX-UHFFFAOYSA-N 0.000 claims 1
- JEDVKUHCDPPWNR-UHFFFAOYSA-N 3h-thieno[2,3-d]pyrimidin-4-one Chemical compound O=C1NC=NC2=C1C=CS2 JEDVKUHCDPPWNR-UHFFFAOYSA-N 0.000 claims 1
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 239000007868 Raney catalyst Substances 0.000 claims 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 claims 1
- 229910000564 Raney nickel Inorganic materials 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical group O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims 1
- 229910000102 alkali metal hydride Inorganic materials 0.000 claims 1
- 150000008046 alkali metal hydrides Chemical class 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000003282 alkyl amino group Chemical group 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 150000008064 anhydrides Chemical class 0.000 claims 1
- 239000000010 aprotic solvent Substances 0.000 claims 1
- 150000001543 aryl boronic acids Chemical class 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 125000002393 azetidinyl group Chemical group 0.000 claims 1
- 239000002585 base Substances 0.000 claims 1
- BNBQRQQYDMDJAH-UHFFFAOYSA-N benzodioxan Chemical compound C1=CC=C2OCCOC2=C1 BNBQRQQYDMDJAH-UHFFFAOYSA-N 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 238000009835 boiling Methods 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- 125000004663 dialkyl amino group Chemical group 0.000 claims 1
- 238000006193 diazotization reaction Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 238000010438 heat treatment Methods 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 150000003949 imides Chemical class 0.000 claims 1
- PXZQEOJJUGGUIB-UHFFFAOYSA-N isoindolin-1-one Chemical compound C1=CC=C2C(=O)NCC2=C1 PXZQEOJJUGGUIB-UHFFFAOYSA-N 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 150000002901 organomagnesium compounds Chemical class 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical group C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 239000003586 protic polar solvent Substances 0.000 claims 1
- 238000007363 ring formation reaction Methods 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 239000011593 sulfur Substances 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 claims 1
- 125000003396 thiol group Chemical class [H]S* 0.000 claims 1
- 229910052725 zinc Inorganic materials 0.000 claims 1
- 239000011701 zinc Substances 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0124627.1A GB0124627D0 (en) | 2001-10-15 | 2001-10-15 | Novel compounds |
| PCT/US2002/032740 WO2003033480A1 (en) | 2001-10-15 | 2002-10-15 | Lactam derivatives as antagonists for human 11cby receptors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005508966A JP2005508966A (ja) | 2005-04-07 |
| JP2005508966A5 true JP2005508966A5 (https=) | 2006-01-05 |
Family
ID=9923785
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003536216A Pending JP2005510487A (ja) | 2001-10-15 | 2002-10-15 | メラニン凝集ホルモン受容体１としてのピリミジノン類 |
| JP2003536220A Pending JP2005508966A (ja) | 2001-10-15 | 2002-10-15 | ヒト１１ＣＢｙ受容体に対する拮抗薬としてのラクタム誘導体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003536216A Pending JP2005510487A (ja) | 2001-10-15 | 2002-10-15 | メラニン凝集ホルモン受容体１としてのピリミジノン類 |
Country Status (21)
| Country | Link |
|---|---|
| EP (2) | EP1436267B1 (https=) |
| JP (2) | JP2005510487A (https=) |
| KR (2) | KR20040045833A (https=) |
| CN (2) | CN1596247A (https=) |
| AT (2) | ATE349434T1 (https=) |
| BR (2) | BR0213242A (https=) |
| CA (2) | CA2463509A1 (https=) |
| CO (2) | CO5580779A2 (https=) |
| CZ (2) | CZ2004499A3 (https=) |
| DE (2) | DE60218721T2 (https=) |
| ES (2) | ES2279009T3 (https=) |
| GB (1) | GB0124627D0 (https=) |
| HU (2) | HUP0402335A3 (https=) |
| IL (2) | IL160872A0 (https=) |
| MX (2) | MXPA04003532A (https=) |
| NO (2) | NO20041504L (https=) |
| NZ (1) | NZ531911A (https=) |
| PL (2) | PL370587A1 (https=) |
| RU (1) | RU2004110053A (https=) |
| WO (2) | WO2003033480A1 (https=) |
| ZA (2) | ZA200402672B (https=) |
Families Citing this family (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL161717A0 (en) | 2001-11-26 | 2004-09-27 | Schering Corp | Piperidine-based mch antagonists for treatment of obesity and cns disorders |
| CA2468015A1 (en) | 2001-11-27 | 2003-06-05 | Merck & Co., Inc. | 2-aminoquinoline compounds |
| DE10238865A1 (de) * | 2002-08-24 | 2004-03-11 | Boehringer Ingelheim International Gmbh | Neue Carbonsäureamid-Verbindungen mit MCH-antagonistischer Wirkung, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| US7351719B2 (en) | 2002-10-31 | 2008-04-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds |
| US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| US20060194871A1 (en) * | 2003-04-11 | 2006-08-31 | Barvian Kevin K | Heterocyclic mchr1 antagoists |
| CN100418965C (zh) * | 2003-08-15 | 2008-09-17 | 万有制药株式会社 | 咪唑并吡啶衍生物 |
| KR100747042B1 (ko) * | 2003-08-19 | 2007-08-07 | 솔젠트 (주) | 신물질６-메틸-３-펜에틸-３,４-디히드로-１ｈ-큐나졸린-２-티온,이의 제조방법 및 이를 유효성분으로 포함하는 미백 효능조성물 |
| US20070078125A1 (en) * | 2003-10-23 | 2007-04-05 | Glaxo Group Limited | Arylamine mch r1 antagonists |
| US7592373B2 (en) | 2003-12-23 | 2009-09-22 | Boehringer Ingelheim International Gmbh | Amide compounds with MCH antagonistic activity and medicaments comprising these compounds |
| UA83416C2 (en) | 2004-02-13 | 2008-07-10 | Баниу Фармасьютикал Ко., Лтд. | Fused ring 4-oxopyrimidine derivative |
| DE102004010893A1 (de) * | 2004-03-06 | 2005-09-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue ß-Ketoamid-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel |
| US7605176B2 (en) | 2004-03-06 | 2009-10-20 | Boehringer Ingelheim International Gmbh | β-ketoamide compounds with MCH antagonistic activity |
| US20080125403A1 (en) | 2004-04-02 | 2008-05-29 | Merck & Co., Inc. | Method of Treating Men with Metabolic and Anthropometric Disorders |
| DE102004017934A1 (de) | 2004-04-14 | 2005-11-03 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel |
| US7524862B2 (en) | 2004-04-14 | 2009-04-28 | Boehringer Ingelheim International Gmbh | Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds |
| US7902356B2 (en) | 2004-12-17 | 2011-03-08 | Eli Lilly And Company | Thiazolopyridinone derivates as MCH receptor antagonists |
| WO2006085692A1 (ja) * | 2005-02-14 | 2006-08-17 | Banyu Pharmaceutical Co., Ltd | ４（３ｈ）－キナゾリノン誘導体の結晶 |
| US7989445B2 (en) | 2005-04-28 | 2011-08-02 | Takeda Pharmaceutical Company Limited | Thienopyrimidone compound |
| WO2007011286A1 (en) * | 2005-07-15 | 2007-01-25 | Astrazeneca Ab | Therapeutic agents |
| KR20080042158A (ko) * | 2005-08-31 | 2008-05-14 | 셀진 코포레이션 | 이소인돌-이미드 화합물과 이를 포함하는 조성물 및 이를이용한 방법 |
| KR101384132B1 (ko) * | 2005-10-19 | 2014-04-10 | 깃세이 야쿠힌 고교 가부시키가이샤 | 축합 복소환 유도체, 그것을 함유하는 의약 조성물 및 그의약 용도 |
| US8618115B2 (en) * | 2005-10-26 | 2013-12-31 | Bristol-Myers Squibb Company | Substituted thieno[3,2-d]pyrimidinones as MCHR1 antagonists and methods for using them |
| US7745447B2 (en) * | 2005-10-26 | 2010-06-29 | Bristol-Myers Squibb Company | Substituted thieno[3,2-D]pyrimidines as non-basic melanin concentrating hormone receptor-1 antagonists |
| US8329704B2 (en) | 2005-12-21 | 2012-12-11 | Janssen Pharmaceutica, N.V. | Substituted pyrazinone derivatives for use in MCH-1 mediated diseases |
| US7553836B2 (en) | 2006-02-06 | 2009-06-30 | Bristol-Myers Squibb Company | Melanin concentrating hormone receptor-1 antagonists |
| EP1987020B1 (en) * | 2006-02-15 | 2012-10-03 | Sanofi | Azacyclyl-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments |
| WO2007093365A2 (en) * | 2006-02-15 | 2007-08-23 | Sanofi-Aventis | Novel amino alcohol-substituted arylthienopyrimidinones, process for their preparation and their use as medicaments |
| KR20080094699A (ko) | 2006-02-15 | 2008-10-23 | 사노피-아벤티스 | 신규 아미노알콜-치환된 아릴디하이드로이소퀴놀리논, 이의제조 방법 및 이의 약물로서의 용도 |
| EP1986646A1 (en) | 2006-02-15 | 2008-11-05 | Sanofi-Aventis | Novel azacycly-substituted arylthienopyrimidinones, process for their preparation and their use as medicaments |
| WO2007142217A1 (ja) * | 2006-06-07 | 2007-12-13 | Banyu Pharmaceutical Co., Ltd. | １－フェニルピリドン誘導体 |
| MX2008015662A (es) | 2006-06-08 | 2009-01-12 | Lilly Co Eli | Nuevos receptores antagonistas de la hormona concentradora de melanina (mch). |
| JP5225269B2 (ja) * | 2006-06-08 | 2013-07-03 | イーライ リリー アンド カンパニー | 新規なｍｃｈ受容体アンタゴニスト |
| JP2010500300A (ja) | 2006-08-08 | 2010-01-07 | サノフィ−アベンティス | アリールアミノアリール−アルキル−置換イミダゾリジン−２，４−ジオン、それらの製造法、それらの化合物を含有する薬剤、およびそれらの使用 |
| WO2008020799A1 (en) | 2006-08-18 | 2008-02-21 | Astrazeneca Ab | Thienopyrimidin-4-one and thienopyridazin-7-one derivatives as mch rl antagonists |
| EP2102208B1 (en) | 2006-12-05 | 2014-04-23 | Janssen Pharmaceutica NV | Novel substituted diaza spiro pyridinone derivatives for use in mch-1 mediated diseases |
| CN101558075A (zh) | 2006-12-14 | 2009-10-14 | 伊莱利利公司 | 5-[4-(氮杂环丁烷-3-基氧基)-苯基]-2-苯基-5H-噻唑并[5,4-c]吡啶-4-酮衍生物及其作为MCH受体拮抗剂的用途 |
| EP2121654A1 (en) | 2007-01-10 | 2009-11-25 | Albany Molecular Research, Inc. | 5-pyridinone substituted indazoles |
| JP2010525077A (ja) | 2007-04-25 | 2010-07-22 | ブリストル−マイヤーズ スクイブ カンパニー | 非塩基性メラニン凝集ホルモン受容体−１アンタゴニスト |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| EP2527360B1 (en) | 2007-06-04 | 2015-10-28 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| DE102007028925A1 (de) | 2007-06-22 | 2008-12-24 | Saltigo Gmbh | Verfahren zur Herstellung von 2-Phenoxyacetalen und den daraus korrespondierenden 2-Phenoxycarbaldehyden |
| KR20100044225A (ko) | 2007-07-21 | 2010-04-29 | 알바니 몰레큘라 리써치, 인크. | 5-피리디논 치환된 인다졸 |
| JP5632612B2 (ja) * | 2007-12-05 | 2014-11-26 | あすか製薬株式会社 | ラクタム化合物又はその塩及びｐｐａｒ活性化剤 |
| PE20091928A1 (es) | 2008-05-29 | 2009-12-31 | Bristol Myers Squibb Co | Tienopirimidinas hidroxisustituidas como antagonistas de receptor-1 de hormona concentradora de melanina no basicos |
| EP2810951B1 (en) | 2008-06-04 | 2017-03-15 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| WO2010003624A2 (en) | 2008-07-09 | 2010-01-14 | Sanofi-Aventis | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
| EP3241839B1 (en) | 2008-07-16 | 2019-09-04 | Bausch Health Ireland Limited | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
| WO2010047982A1 (en) | 2008-10-22 | 2010-04-29 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| JP5557845B2 (ja) | 2008-10-31 | 2014-07-23 | メルク・シャープ・アンド・ドーム・コーポレーション | 糖尿病用剤として有用な新規環状ベンゾイミダゾール誘導体 |
| WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
| CA2689707A1 (en) | 2009-11-16 | 2011-05-16 | Jean-Simon Diallo | Identification of the novel small molecule viral sensitizer vse1 using high-throughput screening |
| MX2012001729A (es) | 2009-08-26 | 2012-06-13 | Sanofi Sa | Nuevos hidratos cristalinos de fluoroglicosido heteroaromatico, productos farmaceuticos que comprenden estos compuestos, y su empleo. |
| US8895596B2 (en) | 2010-02-25 | 2014-11-25 | Merck Sharp & Dohme Corp | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
| US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
| WO2012036233A1 (ja) * | 2010-09-17 | 2012-03-22 | 塩野義製薬株式会社 | メラニン凝集ホルモン受容体アンタゴニスト活性を有する縮合へテロ環誘導体 |
| BR112013021236B1 (pt) | 2011-02-25 | 2021-05-25 | Merck Sharp & Dohme Corp | composto derivado de benzimidazol, e, composição |
| EP2683702B1 (de) | 2011-03-08 | 2014-12-24 | Sanofi | Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| EP2683705B1 (de) | 2011-03-08 | 2015-04-22 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2683698B1 (de) | 2011-03-08 | 2017-10-04 | Sanofi | Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| EP2683699B1 (de) | 2011-03-08 | 2015-06-24 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| US8828995B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| WO2012120052A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| US8871758B2 (en) | 2011-03-08 | 2014-10-28 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
| EP2683701B1 (de) | 2011-03-08 | 2014-12-24 | Sanofi | Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| US8895547B2 (en) | 2011-03-08 | 2014-11-25 | Sanofi | Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof |
| KR101236188B1 (ko) * | 2011-03-10 | 2013-02-22 | 한국화학연구원 | 신규한 피롤로피리디논 유도체 및 그의 ｍｃｈ 수용체-1 관련 질환에 대한 치료학적 용도 |
| HUP1100241A3 (en) | 2011-05-06 | 2013-12-30 | Richter Gedeon Nyrt | Oxetane substituted pyrimidones |
| TW201837023A (zh) | 2011-07-01 | 2018-10-16 | 美商基利科學股份有限公司 | 作為離子通道調節劑之稠合雜環化合物 |
| NO3175985T3 (https=) | 2011-07-01 | 2018-04-28 | ||
| US9527875B2 (en) | 2012-08-02 | 2016-12-27 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| RU2015140066A (ru) | 2013-02-22 | 2017-03-30 | Мерк Шарп И Доум Корп. | Противодиабетические бициклические соединения |
| WO2014139388A1 (en) | 2013-03-14 | 2014-09-18 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
| CA2905438A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
| CA2905435A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
| SI3004138T1 (sl) | 2013-06-05 | 2024-07-31 | Bausch Health Ireland Limited | Ultra čisti agonisti gvanilat ciklaze C, postopek za njihovo pripravo in uporabo |
| WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| BR112016028404A2 (pt) * | 2014-06-05 | 2018-07-03 | Bayer Cropscience Aktiengesellschaft | compostos bicíclicos como pesticidas |
| JP7114076B2 (ja) | 2015-12-22 | 2022-08-08 | シャイ・セラピューティクス・エルエルシー | がん及び炎症性疾患の処置のための化合物 |
| JP6998937B2 (ja) * | 2016-08-12 | 2022-01-18 | バイエル・クロップサイエンス・アクチェンゲゼルシャフト | ２－（２－ジアゾニウム－６－置換フェニル）エタノール塩を環化させることによる４－置換２，３－ジヒドロ－１－ベンゾフラン誘導体の製造方法 |
| EP3509588B1 (en) * | 2016-09-12 | 2023-06-07 | Integral Health,Inc. | Bicyclic compounds useful as gpr120 modulators |
| WO2018049324A1 (en) | 2016-09-12 | 2018-03-15 | Numerate, Inc. | Monocyclic compounds useful as gpr120 modulators |
| US11072602B2 (en) | 2016-12-06 | 2021-07-27 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
| WO2018118670A1 (en) | 2016-12-20 | 2018-06-28 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
| JP7514005B2 (ja) | 2017-06-21 | 2024-07-10 | シャイ・セラピューティクス・エルエルシー | がん、炎症性疾患、ラソパシー、及び線維性疾患の治療のためのｒａｓスーパーファミリーと相互作用する化合物 |
| TW201922724A (zh) | 2017-09-29 | 2019-06-16 | 德商拜耳廠股份有限公司 | 經取代之３－苯基喹唑啉－４（３ｈ）－酮及其用途 |
| WO2019063708A1 (en) | 2017-09-29 | 2019-04-04 | Bayer Aktiengesellschaft | SUBSTITUTED 3-PHENYLQUINAZOLIN-4 (3H) -ONES AND USES THEREOF |
| JP7407461B2 (ja) | 2018-12-19 | 2024-01-04 | シャイ・セラピューティクス・エルエルシー | がん、炎症性疾患、ｒａｓ病、及び線維性疾患の処置のためのｒａｓスーパーファミリーと相互作用する化合物 |
| CN110563730B (zh) * | 2019-07-29 | 2022-03-25 | 江苏理工学院 | 高纯度n10-三氟乙酰蝶酸的制备方法 |
| JP7834721B2 (ja) | 2020-08-28 | 2026-03-24 | アルビナス・オペレーションズ・インコーポレイテッド | 急速進行性線維肉腫タンパク質分解化合物及び関連する使用方法 |
| CN113651800B (zh) * | 2021-09-07 | 2022-08-19 | 山东铂源药业股份有限公司 | 一种甲磺酸奥希替尼的制备方法 |
| EP4584258A1 (en) | 2022-09-07 | 2025-07-16 | Arvinas Operations, Inc. | Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL137227B2 (en) * | 1984-03-28 | 1986-05-31 | Univ Lodzki | Process for preparing novel n-/dialkylaminoalkoxyphenyl/-imides of tetrahydrophtalic acids |
| IL127296A (en) * | 1996-12-31 | 2003-01-12 | Reddy Research Foundation | Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them |
| EP1218336A2 (en) * | 1999-09-20 | 2002-07-03 | Takeda Chemical Industries, Ltd. | Melanin concentrating hormone antagonist |
-
2001
- 2001-10-15 GB GBGB0124627.1A patent/GB0124627D0/en not_active Ceased
-
2002
- 2002-10-15 CN CNA028235932A patent/CN1596247A/zh active Pending
- 2002-10-15 PL PL02370587A patent/PL370587A1/xx not_active Application Discontinuation
- 2002-10-15 CN CNA028204522A patent/CN1571774A/zh active Pending
- 2002-10-15 BR BR0213242-7A patent/BR0213242A/pt not_active Application Discontinuation
- 2002-10-15 CA CA002463509A patent/CA2463509A1/en not_active Abandoned
- 2002-10-15 IL IL16087202A patent/IL160872A0/xx unknown
- 2002-10-15 BR BR0213040-8A patent/BR0213040A/pt not_active IP Right Cessation
- 2002-10-15 JP JP2003536216A patent/JP2005510487A/ja active Pending
- 2002-10-15 NZ NZ531911A patent/NZ531911A/en unknown
- 2002-10-15 ES ES02801693T patent/ES2279009T3/es not_active Expired - Lifetime
- 2002-10-15 AT AT02801693T patent/ATE349434T1/de not_active IP Right Cessation
- 2002-10-15 EP EP02801693A patent/EP1436267B1/en not_active Expired - Lifetime
- 2002-10-15 AT AT02801692T patent/ATE356119T1/de not_active IP Right Cessation
- 2002-10-15 DE DE60218721T patent/DE60218721T2/de not_active Expired - Fee Related
- 2002-10-15 WO PCT/US2002/032740 patent/WO2003033480A1/en not_active Ceased
- 2002-10-15 JP JP2003536220A patent/JP2005508966A/ja active Pending
- 2002-10-15 CZ CZ2004499A patent/CZ2004499A3/cs unknown
- 2002-10-15 KR KR10-2004-7005546A patent/KR20040045833A/ko not_active Withdrawn
- 2002-10-15 CZ CZ2004498A patent/CZ2004498A3/cs unknown
- 2002-10-15 KR KR1020047005548A patent/KR20050043724A/ko not_active Withdrawn
- 2002-10-15 CA CA002463508A patent/CA2463508A1/en not_active Abandoned
- 2002-10-15 RU RU2004110053/04A patent/RU2004110053A/ru not_active Application Discontinuation
- 2002-10-15 EP EP02801692A patent/EP1442025B1/en not_active Expired - Lifetime
- 2002-10-15 MX MXPA04003532A patent/MXPA04003532A/es unknown
- 2002-10-15 ES ES02801692T patent/ES2283647T3/es not_active Expired - Lifetime
- 2002-10-15 DE DE60217147T patent/DE60217147T2/de not_active Expired - Fee Related
- 2002-10-15 IL IL16107402A patent/IL161074A0/xx unknown
- 2002-10-15 PL PL02370138A patent/PL370138A1/xx not_active Application Discontinuation
- 2002-10-15 MX MXPA04003534A patent/MXPA04003534A/es unknown
- 2002-10-15 HU HU0402335A patent/HUP0402335A3/hu unknown
- 2002-10-15 WO PCT/US2002/032739 patent/WO2003033476A1/en not_active Ceased
- 2002-10-15 HU HU0402346A patent/HUP0402346A2/hu unknown
-
2004
- 2004-04-05 ZA ZA200402672A patent/ZA200402672B/en unknown
- 2004-04-13 NO NO20041504A patent/NO20041504L/no not_active Application Discontinuation
- 2004-04-13 ZA ZA200402814A patent/ZA200402814B/en unknown
- 2004-04-13 NO NO20041503A patent/NO20041503L/no not_active Application Discontinuation
- 2004-04-14 CO CO04034241A patent/CO5580779A2/es not_active Application Discontinuation
- 2004-04-14 CO CO04034243A patent/CO5580778A2/es not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005508966A5 (https=) | ||
| RU2004110053A (ru) | Производные лактама в качестве антагонистов 11cby рецепторов человека | |
| KR101714799B1 (ko) | 치환된 5,6-디히드로-6-페닐벤조［ｆ］이소퀴놀린-2-아민 화합물 | |
| JP5997335B2 (ja) | Ｎ含有複素環式化合物 | |
| KR100225720B1 (ko) | 부신피질자극호르몬-방출 인자 길항제로서의 피라졸로피리미딘을 포함하는 약학 조성물 | |
| CA2432578C (en) | Quinazolone derivatives as alpha 1a/b adrenergic receptor antagonists | |
| CN103003278B (zh) | 芳胺基嘌呤衍生物及其制备方法和在医药上的用途 | |
| JP2022081529A (ja) | キナーゼネットワークの阻害剤およびその使用 | |
| JP2022517723A (ja) | Ｃｄｋ阻害剤としての大環状化合物、その製造方法及びその医薬品における応用 | |
| CA2283961A1 (en) | Pyrrolo[2,3d]pyrimidines and their use as tyrosine kinase inhibitors | |
| OA11856A (en) | Aminopyrimidines as sorbitol dehydrogenase inhibitors. | |
| KR20200089718A (ko) | 인돌 화합물 및 이의 용도 | |
| CN107835811B (zh) | 苯胺嘧啶衍生物及其用途 | |
| SK1302001A3 (en) | SUBSTITUTED PYRAZOLE DERIVATIVES CONDENSED WITH SIX-MEMBEREDì (54) HETEROCYCLIC RINGS | |
| EA010487B1 (ru) | Производные тетрагидронафтиридина, пригодные в качестве лигандов рецептора hгистамина | |
| CN1342162A (zh) | 取代的2－芳基－3－(杂芳基)－咪唑并[1,2－a]嘧啶类化合物以及相关的药物组合物和方法 | |
| JP2006522812A5 (https=) | ||
| TW200306837A (en) | Adenosine A2a receptor antagonists | |
| EP4553075A1 (en) | Pi3k inhibitor, preparation method therefor, and use thereof | |
| JP2023520595A (ja) | ピラゾロピリダジノン化合物、その医薬組成物及びその用途 | |
| KR20200055126A (ko) | Ａ2ａ수용체 억제제로서의 축합 고리 유도체 | |
| EP0305093B1 (en) | Imidazo(1,2-b)pyridazine derivatives | |
| CN1334732A (zh) | 嘧啶衍生物在预防和治疗脑缺血中的应用 | |
| JP2006511498A5 (https=) | ||
| US5158953A (en) | 2-substituted methyl-2,3-dihydroimidazo[1,2-c]quinazolin-5(6H)-ones (thiones), the preparation and use thereof |